mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial
暂无分享，去创建一个
L. Kang | Xiaojian Wu | Yunle Wan | Yue Cai | Meijin Huang | P. Lan | S. Luo | Hui Wang | T. Ma | Huabin Hu | Zhi-yang Zhou | Y. Deng | Yan Huang | Jianwei Zhang | J. Ling | Zehua Wu | Xiaoyu Xie | Huaiming Wang | Guangjian Liu | L. Shi | Cailu Shen | Yonghua Cai | Fangqian Li | Lishuo Shi | Yanhong Deng